PUBLISHER: The Business Research Company | PRODUCT CODE: 1938699
PUBLISHER: The Business Research Company | PRODUCT CODE: 1938699
Sheep and goat pox vaccines are specifically developed to prevent diseases caused by viruses belonging to the Capripoxvirus genus, which include sheep pox and goat pox. These vaccines play a critical role in preventing and managing outbreaks among sheep and goat populations, as both diseases can lead to significant economic losses due to high mortality rates and reduced productivity. They function by stimulating the immune system to generate antibodies against the viruses, thereby providing protection from infection.
The primary types of sheep and goat pox vaccines include live attenuated vaccines, inactivated vaccines, and others. Live attenuated vaccines use weakened forms of the virus to stimulate the immune system without causing severe illness. They are particularly effective for diseases such as sheep and goat pox where a robust immune response is necessary for effective protection. These vaccines are administered via various routes such as injectable and intranasal applications for sheep and goats.
Tariffs have influenced the sheep and goat pox vaccines market by increasing the cost of imported vaccine ingredients, adjuvants, and delivery equipment, especially in regions like asia-pacific and africa that rely on imports for advanced vaccines. This has led to higher production costs for multinational manufacturers while encouraging local production and innovation in recombinant and dna-based vaccines. Tariffs have also incentivized regional sourcing strategies and development of cost-effective vaccine solutions for broader livestock coverage.
The sheep and goat pox vaccines market research report is one of a series of new reports from The Business Research Company that provides sheep and goat pox vaccines market statistics, including sheep and goat pox vaccines industry global market size, regional shares, competitors with a sheep and goat pox vaccines market share, detailed sheep and goat pox vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the sheep and goat pox vaccines industry. This sheep and goat pox vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The sheep and goat pox vaccines market size has grown steadily in recent years. It will grow from $60.43 billion in 2025 to $63.19 billion in 2026 at a compound annual growth rate (CAGR) of 4.6%. The growth in the historic period can be attributed to frequent outbreaks of sheep and goat pox, limited availability of early vaccine options, government-led vaccination campaigns, rising livestock population in developing regions, adoption of traditional live attenuated vaccines.
The sheep and goat pox vaccines market size is expected to see steady growth in the next few years. It will grow to $73.74 billion in 2030 at a compound annual growth rate (CAGR) of 3.9%. The growth in the forecast period can be attributed to advancements in recombinant and dna-based vaccine technologies, increasing demand for adjuvanted inactivated vaccines, expansion of preventive veterinary healthcare programs, rising livestock farming investments, growing awareness of biosecurity measures in animal husbandry. Major trends in the forecast period include development of multivalent vaccines for broader protection, rising adoption of injectable vaccines in livestock, increased focus on recombinant and dna-based vaccines, growing awareness of sheep and goat disease prevention, expansion of veterinary vaccination programs in rural regions.
The rising demand for livestock products is expected to drive the growth of the sheep and goat pox vaccines market in the coming years. Livestock products include goods and materials derived from domesticated animals raised in agricultural settings. This demand is increasing due to factors such as income and population growth, urbanization, health concerns, changing consumer preferences, globalization, trade, and economic development. Sheep and goat pox vaccines are crucial for protecting livestock products by preventing disease outbreaks and ensuring the health and productivity of sheep and goat populations. For example, in February 2024, according to the Department for Environment, Food, and Rural Affairs, a UK-based government department, red meat production rose, with mutton and lamb production showing the largest increase of 2.9%. Therefore, growing demand for livestock products is driving growth in the sheep and goat pox vaccines market.
Increasing investment in veterinary research and development (R&D) is also expected to propel the growth of the sheep and goat pox vaccines market. Veterinary R&D investment refers to the allocation of financial resources by governments, private institutions, and organizations to study, innovate, and develop new solutions for improving animal health, including vaccines, treatments, diagnostic tools, and disease prevention strategies. Such investment is rising due to the growing need to innovate and improve animal health solutions in response to emerging and re-emerging livestock diseases. Enhanced investment directly supports the development of more effective and safer vaccines for animals. For instance, in May 2024, according to the Animal and Plant Health Inspection Service (APHIS), a US-based government agency, the USDA awarded over $22.2 million to 81 new projects led by 48 states, universities, industry organizations, and veterinary diagnostic laboratories to strengthen prevention, preparedness, early detection, and rapid response to the most damaging diseases threatening US livestock. Therefore, increasing investment in veterinary R&D is driving growth in the sheep and goat pox vaccines market.
Key players in the sheep and goat pox vaccines market are leveraging strategic partnerships to develop innovative vaccines. Strategic partnerships support the market by combining expertise and resources, advancing R&D, expanding market reach, and accelerating commercialization. For example, in February 2024, Hester Biosciences, an India-based biotechnology and vaccine company, launched a PPR-Goatpox combined vaccine, offering protection against both Peste des Petits Ruminants (PPR) and Goatpox in a single formulation. The combined vaccine simplifies vaccination schedules, reduces handling stress, lowers vaccination costs, and improves overall flock health. This development followed a strategic technology transfer from the Indian Council of Agricultural Research-Indian Veterinary Research Institute (ICAR-IVRI), allowing Hester to commercialize the indigenous vaccine by leveraging IVRI's research expertise alongside Hester's manufacturing and distribution capabilities, thereby enhancing preventive livestock healthcare and vaccine accessibility in endemic regions.
Major companies operating in the sheep and goat pox vaccines market are Indian Immunologicals Ltd., Kemin Industries, Bimeda Biologicals, Hester Biosciences Limited, Dollvet, MSD Animal Health, MCI Sante Animale, Creative Biolabs, Biovex Inc., Advacare Pharma, Brilliant Bio Pharma Private Limited, Intervac (PVT) Ltd., Agrinnovate India Limited, Bio-Med Pvt Limited, JOVAC, Vetal Animal Health Products, Kenya Veterinary Vaccines Production Institute, Vedall Pharma Private Limited, Farmer's Pharma Private Limited, Institute of Veterinary Biological Products
North America was the largest region in the sheep and goat pox vaccines market in 2025. The regions covered in the sheep and goat pox vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the sheep and goat pox vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The sheep and goat pox vaccines market consists of sales of recombinant vaccines and subunit vaccines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Sheep And Goat Pox Vaccines Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses sheep and goat pox vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for sheep and goat pox vaccines ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The sheep and goat pox vaccines market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.